$SGMO slumps to lows -13% after latest update with $PFE on Phase 1/2 trial of their hemophilia A gene therapy -dosing of the 1st patient in the pivotal Phase 3 study is anticipated in 2nd half, 2020 ($BMRN has edged higher in reaction -has its own gene therapy